The forthcoming committee meeting to discuss human alpha1-proteinase inhibitor for treating emphysema on Wednesday 24 October 2018 has been rearranged. This is to enable the company to prepare and submit additional information for consideration by the HST committee.
Human alpha1-proteinase inhibitor for treating emphysema will be now considered by committee on Thursday 14 March 2019.